Go Pro
OTCMKTS:XSNX

NovAccess Global Q4 2024 Earnings Report

NovAccess Global logo
$0.0001 0.00 (0.00%)
As of 07/2/2026 09:31 AM Eastern

NovAccess Global EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NovAccess Global Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NovAccess Global Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NovAccess Global Earnings Headlines

Global wage calculator: Compare your salary
NovAccess Global Inc.
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
NovAccess Global Inc. (XSNX)
See More NovAccess Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovAccess Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovAccess Global and other key companies, straight to your email.

About NovAccess Global

NovAccess Global (OTCMKTS:XSNX), a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

View NovAccess Global Profile